Fresenius appoints Marc-Alexander Mahl to Management Board to oversee Kabi businesses

• Fresenius appointed Marc-Alexander Mahl to its Management Board effective November 1, 2026, replacing Pierluigi Antonelli, who is leaving for personal reasons.
• Mahl, head of Pharma and Nutrition since May 2023, will oversee Fresenius Kabi businesses.
• CFO Sara Hennicken’s contract was extended for five years, through 2032.
• Sébastien Guery, Nutrition head since April 2024, will lead the business as a standalone unit, reporting directly to Mahl.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2416814_en) on October 15, 2026, and is solely responsible for the information contained therein.